Ashley Robshaw
Pfizer (United States)(US)
Publications by Year
Research Areas
Alzheimer's disease research and treatments, Computational Drug Discovery Methods, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography, Cholinesterase and Neurodegenerative Diseases
Most-Cited Works
- → Application of the Bicyclo[1.1.1]pentane Motif as a Nonclassical Phenyl Ring Bioisostere in the Design of a Potent and Orally Active γ-Secretase Inhibitor(2012)420 cited
- → Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors(2011)105 cited
- → Utilizing Structures of CYP2D6 and BACE1 Complexes To Reduce Risk of Drug–Drug Interactions with a Novel Series of Centrally Efficacious BACE1 Inhibitors(2015)78 cited
- → Alternative method of oral administration by peanut butter pellet formulation results in target engagement of BACE1 and attenuation of gavage-induced stress responses in mice(2014)56 cited
- → Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design(2015)46 cited
- → Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality(2016)43 cited
- → Design and Synthesis of Clinical Candidate PF-06751979: A Potent, Brain Penetrant, β-Site Amyloid Precursor Protein Cleaving Enzyme 1 (BACE1) Inhibitor Lacking Hypopigmentation(2018)42 cited
- → Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses(2012)36 cited
- → Quantitative Pharmacokinetic/Pharmacodynamic Analyses Suggest That the 129/SVE Mouse Is a Suitable Preclinical Pharmacology Model for Identifying Small-Molecule γ-Secretase Inhibitors(2011)24 cited
- → Cerebrospinal Fluid β-Amyloid Turnover in the Mouse, Dog, Monkey and Human Evaluated by Systematic Quantitative Analyses(2012)21 cited